The rise in the prevalence of major respiratory disorders is expected to drive the pulmonary drug delivery devices market during the forecast period.Wilmington, Delaware, United States, Nov. 23, 2023 (GLOBE NEWSWIRE) Transparency Market Research Inc. -The global pulmonary drug delivery devices market is projected to flourish at a CAGR of 4.7% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 49.5 billion is anticipated for the market in 2031. As of 2023, the demand for
Arcellx (NASDAQ:ACLX – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations […]
/PRNewswire/ Inherited types of anemia encompass a group of genetic disorders characterized by a deficiency in the production, structure, or function of.
DelveInsight Business Research, LLP: Key Market Analysis of Sickle Cell Disease, Fanconi Anemia, and Diamond-Blackfan Anemia in the Inherited Types of Anemia Therapeutic Space finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.